Clinical Trial

A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a multicenter, single arm, and open design Phase I clinical trial aimed at evaluating the safety, Pharmacokinetics (PK) characteristics, immunogenicity, and preliminary efficacy of TQB2252 injection in subjects with advanced malignant tumors.
Trial Details
NCT Number NCT06649656
Lead Sponsor Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
Conditions Advanced Cancers
Enrollment 100 participants
Start Date 2024-11
Primary Completion 2026-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-10-21